The Ministry of Health of Russia issued registration certificate to Rapharma’s Oliramus drug

14 June 2022

GxPnews

Rapharma received registration certificate ËÏ-¹(000744)-(ÐÃ-RU) for its drug Oliramus drug (INN Everolimus) from the Ministry of Health of the Russian Federation. The drug will be available to patients in three dosages (2.5 mg, 5 mg, and 10 mg). This is reported on the company’s official website.

Oliramus antitumor therapy is a protein kinase inhibitor  (mammalian target of rapamycin (mTOR) inhibitor) for oral administration. The drug is indicated for adult patients with the following conditions:

“Oliramus acts by suppressing protein kinase, thereby reducing blood supply to the tumor and slowing down the growth and spread of cancer cells. The efficacy, tolerability and safety of Everolimus has been confirmed in a large number of clinical trials,” the report says.

AO Rapharma, together with ZAO PharmFirma Sotex, forms the basis of the production segment of Protek group, the company stressed.

Source

Print

Our news

All news

Media Center

Read more